China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Cash from Financing Activities came in at -$79325.0 in Q1 2026, down 3.26% YoY from -$81998.9 in Q1 2025, and down 9.28% on a QoQ basis from -$72592.0 in Q4 2025.
China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 16 years of Cash from Financing Activities data on file, last reported at -$79325.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 3.26% year-over-year to -$79325.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$296532.0 (down 152.46% YoY) and the FY2025 annual result came in at -$294027.0, down 770.37% from the prior year.
- Cash from Financing Activities retreated to -$79325.0 in Q1 2026, from -$72592.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $518237.0 in Q1 2023 to a low of -$850555.0 in Q2 2022.
- A 5-year average of -$123764.5 and a median of -$54333.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 633.62% — and 2025, when it tumbled 1885.97%.
- Tracing CPHI's Cash from Financing Activities over 5 years: stood at -$672063.0 in 2022, then jumped by 104.52% to $30378.0 in 2023, then sank by 278.86% to -$54333.0 in 2024, then slumped by 33.61% to -$72592.0 in 2025, then dropped by 9.28% to -$79325.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$79325.0 (Q1 2026), -$72592.0 (Q4 2025), and -$122214.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | 120,118.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,325.00 |
| Mar 31, 2026 | -79,325.00 |
| Dec 31, 2025 | -72,592.00 |
| Dec 31, 2025 | -72,592.00 |
| Sep 30, 2025 | -122,214.00 |
| Sep 30, 2025 | -122,214.00 |
| Jun 30, 2025 | -22,401.00 |
| Jun 30, 2025 | -22,401.00 |
| Mar 31, 2025 | -76,820.00 |
| Mar 31, 2025 | -76,820.00 |
| Dec 31, 2024 | -54,333.00 |
| Dec 31, 2024 | -54,333.00 |
| Sep 30, 2024 | 6,843.00 |
| Sep 30, 2024 | 6,843.00 |
| Jun 30, 2024 | 6,852.00 |
| Jun 30, 2024 | 6,852.00 |
| Mar 31, 2024 | 6,856.00 |
| Mar 31, 2024 | 6,856.00 |
| Dec 31, 2023 | 30,378.00 |
| Dec 31, 2023 | 30,378.00 |